Want to know what's happening next in healthcare?

MedCityNews is the leading online news source for the business of innovation in healthcare.


“MedCity is invaluable among the many sources of industry reporting because the team endeavor to bring the truly new, and innovative opportunities and developments to light.”

Ken Kirby, President, Transdermal Delivery Solutions Corp


Sign up for our daily newsletter


FDA warns shorter name of new Roche cancer drug may cause confusion

11:01 am by | 0 Comments

FDA drug

(Reuters) WASHINGTON - The U.S. health regulator warned on Monday that using a shorter name for Roche's new breast cancer drug Kadcyla may lead to the treatment being confused with an older therapy and cause potential harm to patients.

The Food and Drug Administration issued a warning on its website saying that some third-party publications, health information systems and websites were incorrectly using a truncated version of Kadcyla's generic name.

Kadcyla, generically known as ado-trastuzumab emtansine, was being referred to as "trastuzumab emtansine," which can lead to the drug being confused with Roche's blockbuster breast cancer drug Herceptin, generically known as trastuzumab.

The dosing and treatment schedules for Kadcyla and Herceptin are quite different, so confusion between these products could lead to dosing errors and potential harm to patients, the FDA said on its website. (http://link.reuters.com/guh87t)

Health care professionals should use both the brand name Kadcyla and the generic name while communicating medication orders and in computerized order entry systems, the regulator said.

No medication errors related to the confusion between Kadcyla and Herceptin were reported to the FDA since Kadcyla's approval on February 22, the FDA said, adding that medication errors had occurred during the clinical trials testing the drug's safety and efficacy before the approval.

(Reporting by Esha Dey in Bangalore; Editing by Roshni Menon)

Copyright 2014 MedCity News. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
0 comments